Literature DB >> 8425199

Growth inhibition of a human colorectal carcinoma cell line by interleukin 1 is associated with enhanced expression of gamma-interferon receptors.

A B Raitano1, M Korc.   

Abstract

Recombinant human tumor necrosis factor and recombinant human gamma interferon (IFN-gamma) exert synergistic growth inhibitory effects in WiDR human colorectal carcinoma cells. In this cell line, tumor necrosis factor increases IFN-gamma binding. Interleukin 1 (IL-1) is a cytokine that mimics many of the biological actions of TNF. Therefore, in the present study, we investigated the effects of recombinant human IL-1 on cell growth and IFN-gamma receptor expression in WiDR cells. IL-1 slightly inhibited the growth of WiDR cells, and exerted additive growth inhibitory effects in the presence of IFN-gamma. IL-1 caused a time- and dose-dependent increase in 125I-labeled IFN-gamma binding that was maximal at 6 h, persisted for at least 24 h, and was blocked by both actinomycin D and cycloheximide. The increase in binding was associated with an increase in cell surface IFN-gamma receptor protein expression as determined by Scatchard analysis of equilibrium binding data and by immunofluorescent staining with an anti-human IFN-gamma receptor monoclonal antibody. IL-1 also produced a time- and dose-dependent increase in IFN-gamma receptor mRNA levels that was maximal at 3 h and persisted for at least 24 h. Actinomycin D, but not cycloheximide, completely blocked the IL-1-mediated increase in IFN-gamma receptor mRNA levels. However, IL-1 did not alter IFN-gamma receptor mRNA half-life. These data indicate that IL-1 and IFN-gamma exert additive growth inhibitory effects on colon cancer cell growth, and suggest that IL-1 increases IFN-gamma receptor expression in these cells by enhancing IFN-gamma mRNA levels.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8425199

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Probiotics and immune response.

Authors:  Stephanie Blum; Dirk Haller; Andrea Pfeifer; Eduardo J Schiffrin
Journal:  Clin Rev Allergy Immunol       Date:  2002-06       Impact factor: 8.667

2.  A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion.

Authors:  H C Jung; L Eckmann; S K Yang; A Panja; J Fierer; E Morzycka-Wroblewska; M F Kagnoff
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

3.  Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures.

Authors:  D Haller; C Bode; W P Hammes; A M Pfeifer; E J Schiffrin; S Blum
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

4.  The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.

Authors:  A B Raitano; J R Halpern; T M Hambuch; C L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

5.  Inflammatory cytokines stimulate the adhesion of colon carcinoma cells to mesothelial monolayers.

Authors:  W M U van Grevenstein; L J Hofland; M E E van Rossen; P M van Koetsveld; J Jeekel; C H J van Eijck
Journal:  Dig Dis Sci       Date:  2007-03-30       Impact factor: 3.199

6.  Inhibition of growth of normal and human papillomavirus-transformed keratinocytes in monolayer and organotypic cultures by interferon-gamma and tumor necrosis factor-alpha.

Authors:  P Delvenne; W al-Saleh; C Gilles; A Thiry; J Boniver
Journal:  Am J Pathol       Date:  1995-03       Impact factor: 4.307

7.  Suppression of metastasis-associated S100A4 gene expression by gamma-interferon in human colon adenocarcinoma cells.

Authors:  K Takenaga
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

8.  Malignant germ cell tumours of the testis express interferon-gamma, but are resistant to endogenous interferon-gamma.

Authors:  S Schweyer; A Soruri; J Peters; A Wagner; H J Radzun; A Fayyazi
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.